Seeking Alpha

Arena (ARNA) transfers the marketing rights for its Belviq diet drug to partner Eisai...

Arena (ARNA) transfers the marketing rights for its Belviq diet drug to partner Eisai (ESALY.PK), which will market the pill in the U.S. and apply for authorization in other countries in the Americas. SA author Red Acre Investments notes that what is not explicitly stated is that Eisai, not Arena, will run all of the pediatric and cardiovascular outcome trials that are required under Belviq's FDA approval letter (.pdf). (PR)
Comments (1)
  • topperg
    , contributor
    Comments (218) | Send Message
     
    ARNA $30---$50 buyout say no more we wait
    30 Jul 2012, 12:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector